{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:39:10Z","timestamp":1777045150746,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-03916-3","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:27:09Z","timestamp":1740130029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A retrospective study evaluating the effect of trastuzumab addition to carboplatin\/paclitaxel on overall survival in patients with advanced-stage HER2\/neu-overexpressing uterine serous carcinoma or carcinosarcoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Ting-Fang","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lou","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hsiang","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Tien","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ku","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheau-Feng","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hsing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"3916_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4: e214708.","journal-title":"JAMA Netw Open"},{"key":"3916_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"3916_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jnci\/djx214","volume":"110","author":"J Lortet-Tieulent","year":"2018","unstructured":"Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978\u20132013. J Natl Cancer Inst. 2018;110:354\u201361.","journal-title":"J Natl Cancer Inst"},{"key":"3916_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2021.04.029","volume":"162","author":"G Bogani","year":"2021","unstructured":"Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Uterine serous carcinoma. Gynecol Oncol. 2021;162:226\u201334.","journal-title":"Gynecol Oncol"},{"key":"3916_CR5","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1111\/jog.14797","volume":"47","author":"Y Han","year":"2021","unstructured":"Han Y, Liu C. Clinicopathological characteristics and prognosis of uterine serous carcinoma: A SEER program analysis of 1016 cases. J Obstet Gynaecol Res. 2021;47:2460\u201372.","journal-title":"J Obstet Gynaecol Res"},{"key":"3916_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ygyno.2003.10.031","volume":"91","author":"KC Podratz","year":"2003","unstructured":"Podratz KC, Mariani A. Uterine papillary serous carcinomas: The exigency for clinical trials. Gynecol Oncol. 2003;91:461\u20132.","journal-title":"Gynecol Oncol"},{"key":"3916_CR7","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1111\/1471-0528.13726","volume":"123","author":"JF Lin","year":"2016","unstructured":"Lin JF, Mu\u00f1iz K, Sukumvanich P, Gehrig P, Beriwal S, Kelley JL, et al. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: A National Cancer Database study. BJOG. 2016;123:1846\u201352.","journal-title":"BJOG"},{"key":"3916_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/IGC.0000000000000844","volume":"27","author":"M McGunigal","year":"2017","unstructured":"McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: A National Cancer Database analysis. Int J Gynecol Cancer. 2017;27:85\u201392.","journal-title":"Int J Gynecol Cancer"},{"key":"3916_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","volume":"115","author":"DM Boruta 2nd","year":"2009","unstructured":"Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142\u201353.","journal-title":"Gynecol Oncol"},{"key":"3916_CR10","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.2001.19.20.4048","volume":"19","author":"PJ Hoskins","year":"2001","unstructured":"Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study. J Clin Oncol. 2001;19:4048\u201353.","journal-title":"J Clin Oncol"},{"key":"3916_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ygyno.2012.07.112","volume":"127","author":"AP Kiess","year":"2012","unstructured":"Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, et al. Five-year outcomes of adjuvant carboplatin\/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol. 2012;127:321\u20135.","journal-title":"Gynecol Oncol"},{"key":"3916_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3916_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/ijgo.14033","volume":"158","author":"A Raffone","year":"2022","unstructured":"Raffone A, Travaglino A, Raimondo D, Maletta M, De Vivo V, Visiello U, et al. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival. Int J Gynaecol Obstet. 2022;158:520\u20137.","journal-title":"Int J Gynaecol Obstet"},{"key":"3916_CR14","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1097\/IGC.0000000000000228","volume":"24","author":"D Berton-Rigaud","year":"2014","unstructured":"Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24:S55-60.","journal-title":"Int J Gynecol Cancer"},{"key":"3916_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ygyno.2009.10.053","volume":"116","author":"J Gonzalez Bosquet","year":"2010","unstructured":"Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010;116:419\u201323.","journal-title":"Gynecol Oncol"},{"key":"3916_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","volume":"33","author":"D Rottmann","year":"2020","unstructured":"Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, et al. HER2 testing of gynecologic carcinosarcomas: Tumor stratification for potential targeted therapy. Mod Pathol. 2020;33:118\u201327.","journal-title":"Mod Pathol"},{"key":"3916_CR17","doi-asserted-by":"crossref","unstructured":"Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, et al. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I). In: chemotherapy-na\u00efve patients with stage I-IV, persistent, or recurrent uterine or ovarian carcinosarcoma: An NRG Oncology trial. J Clin Oncol. 2019;40:968\u201377.","DOI":"10.1200\/JCO.2019.37.15_suppl.5500"},{"key":"3916_CR18","first-page":"301","volume":"22","author":"EK Lee","year":"2024","unstructured":"Lee EK, Liu JF. Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies. Clin Adv Hematol Oncol. 2024;22:301\u201310.","journal-title":"Clin Adv Hematol Oncol"},{"key":"3916_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","volume":"159","author":"BK Erickson","year":"2020","unstructured":"Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, et al. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecol Oncol. 2020;159:17\u201322.","journal-title":"Gynecol Oncol"},{"key":"3916_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39\u201351.","journal-title":"N Engl J Med"},{"key":"3916_CR21","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol. 2018;36:2044\u201351.","journal-title":"J Clin Oncol"},{"key":"3916_CR22","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"AN Fader","year":"2020","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): Updated overall survival analysis. Clin Cancer Res. 2020;26:3928\u201335.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"3916_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","volume":"2023","author":"N Abu-Rustum","year":"2023","unstructured":"Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, et al. Uterine neoplasms. Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;2023(21):181\u2013209.","journal-title":"J Natl Compr Canc Netw"},{"key":"3916_CR24","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.clbc.2020.08.006","volume":"21","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. Trastuzumab deruxtecan (DS-8201a): The latest research and advances in breast cancer. Clin Breast Cancer. 2021;21:e212\u20139.","journal-title":"Clin Breast Cancer"},{"key":"3916_CR25","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.22.02558","volume":"41","author":"T Nishikawa","year":"2023","unstructured":"Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial. J Clin Oncol. 2023;41:2789\u201399.","journal-title":"J Clin Oncol"},{"key":"3916_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 Phase II trial. J Clin Oncol. 2024;42:47\u201358.","journal-title":"J Clin Oncol"},{"key":"3916_CR27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","volume":"15","author":"N Mohan","year":"2016","unstructured":"Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ. Trastuzumab, but not pertuzumab, dysregulates HER2 Signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther. 2016;15:1321\u201331.","journal-title":"Mol Cancer Ther"},{"key":"3916_CR28","doi-asserted-by":"crossref","unstructured":"Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, et al. Systemic treatment of HER2- overexpression metastatic breast cancer: A systematic review. Asia Pac J Clin Oncol. 2014;10 Suppl S4:1\u201314.","DOI":"10.1111\/ajco.12206"},{"key":"3916_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215\u201321.","journal-title":"J Clin Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03916-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:27:14Z","timestamp":1740130034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03916-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3916"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03916-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4372638\/v1","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TriNetX Research Network is fully compliant with the HIPAA and holds a waiver from the Western Institutional Review Board, given the deidentified and aggregate nature of the data. This manuscript presents original work and has not been previously published, nor is it under consideration for publication elsewhere. All authors have significantly contributed to the conception, design, analysis, or interpretation of the data presented in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The Consent for Publication of the Subjects in This Study Was Not Applicable, As the Data Collected Is Sourced from Electronic Health Records Obtained from the TriNetX Research Network in Cambridge, MA, USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}